As the biotechnology sector remains flat-to-down year-to-date, Wedbush analysts David Nierengarten and Heather Behanna weighed in on a handful of stocks on October …
Maxim’s healthcare analyst Jason McCarthy weighed in today with an optimistic view on bluebird bio Inc (NASDAQ:BLUE), after spending an evening with bluebird management and clients, …
Roth Capital analyst Debjit Chattopadhyay weighed in today with a favorable report on bluebird bio Inc (NASDAQ:BLUE), reiterating a Buy rating and $192 price target, which implies …
Recently, various executives have taken part in insider selling activity for the stocks of Celgene Corporation (NASDAQ:CELG), Palo Alto Networks Inc (NYSE:PANW), Yelp Inc. (NYSE:YELP), and bluebird …
Recently, various executives in the healthcare industry have taken part in insider selling activity for the stocks of Gilead Sciences, Inc. (NASDAQ:GILD), bluebird bio Inc (NASDAQ:BLUE), …
Roth Capital analyst Debjit Chattopadhyay issued a note to investors on August 25 highlighting the recent stock market drop. However, the analyst found …
J.P.
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based …
On August 2, Roth Capital analyst Debjit Chattopadhyay published a report providing a list of upcoming catalysts for several biotechnology companies including Sarepta Therapeutics Inc (NASDAQ:SRPT), Bluebird Bio Inc (NASDAQ:BLUE), and Agios …
On August 2, Roth Capital analyst Debjit Chattopadhyay published a report providing a list of upcoming catalysts for several biotechnology companies including Sarepta Therapeutics Inc (NASDAQ:SRPT),Bluebird Bio Inc (NASDAQ:BLUE), and Agios Pharmaceuticals …
